Humedix
Financials
Valuation Metrics
Humedix's Market Cap is ₩2852B. At end of 2025 it was ₩4531B. Ranked #649 of 2,436 in KR market (top 27%), #264 of 1,649 on KOSDAQ (top 16%), #72 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 285.24B KRW | KR#649/2,436 Sec#72/234 |
| Revenue | 170.43B KRW | KR#1,095/2,436 Sec#66/234 |
| Net Income | 51.35B KRW | KR#362/2,436 Sec#25/234 |
| Total Assets | 338.44B KRW | KR#944/2,436 Sec#61/234 |
| Net Assets | 310.60B KRW | KR#689/2,436 Sec#44/234 |
| Employees | 371 | KR#647/2,436 Sec#57/234 |
| Value | ||
| P/E | 5.55x | KR#342/2,436 Sec#12/234 |
| P/B | 0.92x | KR#1,412/2,436 Sec#90/234 |
| P/S | 1.67x | KR#1,732/2,436 Sec#97/234 |
| EV/EBITDA | 5.91x | KR#290/2,436 Sec#8/234 |
| FCF Yield | 13.05% | KR#518/2,436 Sec#17/234 |
| Profitability | ||
| ROE | 16.53% | KR#192/2,436 Sec#12/234 |
| ROA | 15.17% | KR#73/2,436 Sec#9/234 |
| Op. Margin | 23.36% | KR#105/2,436 Sec#15/234 |
| Revenue Growth | 0.95% | KR#1,380/2,436 Sec#131/234 |
| Earnings Growth | -3.23% | KR#930/2,436 Sec#63/234 |
| Financial Health | ||
| Debt Ratio | 108.96% | KR#417/2,436 Sec#59/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 37.21B KRW | KR#355/2,436 Sec#21/234 |
| Cash | 50.10B KRW | KR#750/2,436 Sec#47/234 |
| Current Ratio | 8.03x | KR#142/2,436 Sec#35/234 |
| Net Debt/EBITDA | -1.26x | KR#412/2,436 Sec#22/234 |
| Dividend | ||
| Div. Yield | 3.75% | KR#503/2,436 Sec#17/234 |
| Div. Growth | 46.03% | KR#256/2,436 Sec#9/234 |
| Performance | ||
| 1Y Return | -58.36% | KR#2,216/2,436 Sec#209/234 |
| 1M Return | -6.27% | KR#1,497/2,436 Sec#149/234 |
| From 52W High | -65.77% | KR#1,989/2,436 Sec#170/234 |
| 1Y MDD | -70.18% | KR#1,955/2,436 Sec#168/234 |
| Trading | ||
| Volume | 22,670 shares | KR#1,792/2,436 Sec#182/234 |
| Foreign Own. | 8.21% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 4,573 KRW | KR#187/2,436 Sec#12/234 |
| BPS | 27,976 KRW | KR#380/2,436 Sec#27/234 |
Company Info
Humedix, established in 2003 for the manufacturing and sale of functional foods, changed its name from its original in 2010 and was listed on KOSDAQ in 2014. Through research and development of hyaluronic acid and PDRN, the company produces and supplies fillers, botulinum toxin, arthritis therapeutics, and cosmetics to domestic and international healthcare markets. Humedix strengthens its market presence by acquiring European CE and Chinese NMPA certifications for its proprietary HI method fillers. It maximizes synergy through heparin sodium localization and an aesthetic solution portfolio, and is headquartered in Seongnam-si, Gyeonggi-do.